Bespak announces completion of a development agreement with Zogenix, a pharmaceutical company focused on the development and commercialisation of medicines to treat the central nervous system (CNS)
The device development agreement is focussed on assisting Zogenix to commercialise its sumatriptan Intraject delivery system, which is a needle free, single use, disposable, subcutaneous delivery technology designed to provide the fastest possible relief of migraine.
Bespak commercial manager Scott Kellogg commented: "We are delighted that this agreement has been finalised and we look forward to working closely with Zogenix to ensure the commercial success of the sumatriptan Intraject delivery system".
"In the near future we are focused on finalising a supply agreement for the actuator assembly and other components of the Intraject device".
Stephen Farr, president and COO of Zogenix added "We are currently building towards commercial manufacturing with an anticipated 505(b)2 NDA submission in 2007.
"We look forward to working with Bespak to accelerate our progress towards full scale commercial launch."
